Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic SyndromesElisabetta Sauta, Matteo Giovanni Della Porta, Esther Natalie Olíva et al.|Journal of Clinical Oncology|2023Cited by 109
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)Cristina Astrid Tentori, Najla H. Al Ali, Elena Riva et al.|Blood|2023Cited by 5
Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic SyndromesElisabetta Sauta, Matteo Giovanni Della Porta, Lin-Pierre Zhao et al.|Blood|2022Cited by 4
Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory/relapsed Hodgkin lymphoma: A retrospective analysisJacopo Mariotti, Stéfania Bramanti, Chiara De Philippis et al.|British Journal of Haematology|2025Cited by 1